Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (101-110 of 234) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2020
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 1, 2019
Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancerSunil Parimi, Suraya Bondy, Erica Tsang, et al.
European Urology|November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 TrialKate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Pageof 24

Showing results (101-110 of 234) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2020
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 1, 2019
Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancerSunil Parimi, Suraya Bondy, Erica Tsang, et al.
European Urology|November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 TrialKate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 14, 2022
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in CanadaShamini Selvarajah, Kasmintan A Schrader, Michael P Kolinsky, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Pageof 24